BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Viable Tips for Seniors to Purchase a Minimal expense Jeep Wrangler - 2France's Senate backs ban on social media platforms for under-15s
- 3When the moon hits your eye from your Orion ship up high, that's a 'mare'
- 4‘Democratizing space’ is more than just adding new players – it comes with questions around sustainability and sovereignty
- 5'Stranger Things' made him a heartthrob. He left Hollywood anyway.
- Compassion and Association: Building Significant Connections
- AstraZeneca to acquire Modella AI to speed oncology drug research
- Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts
- Family-Accommodating Snow Sports Experiences
- Why screening for the deadliest cancer in the U.S. misses most cases
- Spotify Wrapped and Apple Music Replay are here: Top songs, albums and artists of 2025
- Israel says it killed armed Hamas 'terrorists' in Gaza
- Former IRGC child executioner tells ‘Post’ how he became devout Christian dissident
- Vote in favor of your Number one kind of juice
